-
Join Us
-
Company Culture
-
Hot Job Openings
-
Investor Relations
Friday August 29 ，2025
2025 Interim Results Earnings Call
Dear Investors:
Hua Medicine (2552.HK) cordially invites you or your representative to attend the conference call for the Company’s 2025 Interim results, which will be held 8:00 AM HKT, August 29, 2025 (Friday).
During the conference call, management will provide a review of the Company’s first half year financial results in 2025, business updates, as well as address plans for the future.
Details of the earnings call are as follows:
Date: | August 29,2025 |
Time： | Login starts: 7:45AM HKT |
Duration: | Approximately 60mins (including Q&A session) |
Language: | English |
Management: |
Dr. Li Chen, Founder and CEO |
RSVP: | Webinar Link : |
About Hua Medicine
Hua Medicine (The "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁?) (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing (华堂宁?) was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
